Nivolumab
Phase 2Terminated 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Colon Adenoma
Conditions
Colon Adenoma, Colon Carcinoma, Lynch Syndrome, MLH1 Gene Mutation, MSH2 Gene Mutation
Trial Timeline
Oct 4, 2018 → Jan 25, 2021
NCT ID
NCT03631641About Nivolumab
Nivolumab is a phase 2 stage product being developed by Bristol Myers Squibb for Colon Adenoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT03631641. Target conditions include Colon Adenoma, Colon Carcinoma, Lynch Syndrome.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03126643 | Pre-clinical | Completed |
| NCT02475382 | Pre-clinical | Completed |
| NCT06523621 | Phase 2 | Recruiting |
| NCT06499298 | Pre-clinical | Completed |
| NCT06735781 | Pre-clinical | Completed |
| NCT06421311 | Pre-clinical | Terminated |
| NCT06452329 | Pre-clinical | Completed |
| NCT06003075 | Phase 2 | Terminated |
| NCT06361576 | Pre-clinical | Completed |
| NCT06361563 | Pre-clinical | Completed |
| NCT05068609 | Pre-clinical | Completed |
| NCT04936399 | Pre-clinical | Completed |
| NCT04205409 | Phase 2 | Active |
| NCT04401774 | Phase 2 | Completed |
| NCT04361058 | Phase 1 | Withdrawn |
| NCT04022980 | Phase 1 | Completed |
| NCT04019964 | Phase 2 | Completed |
| NCT04146324 | Pre-clinical | Completed |
| NCT04099251 | Phase 3 | Active |
| NCT03981146 | Phase 2 | Active |
Competing Products
20 competing products in Colon Adenoma